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Abstract 
AIM: Compare itraconazole alone, fluconazole combined with ketoconazole and ketoconazole in the treatment of 
patients with pityriasis versicolor. 
MATERIAL AND METHODS: A group of 240 pityriasis versicolor patients (confirmed with KOH and culture) were 
classified into 3 groups: Fluconazole 300 mg a week and 2% ketoconazole foam twice a week for 2 weeks 
(Category I), Itraconazole 200 mg daily for one week (category II); Ketoconazole 2% foam daily for 2 weeks 
(Category 3). Clinical (colour of macule, scale, pruritus) and mycological assessment were done after 4 weeks of 
therapy. 
RESULTS: After 4 weeks of treatment, clinical cure was observed in 62.4% (Category I), 36.3% (Category II) and 
37.5% (Category III).  
CONCLUSION: It was reported in our study that the most effective regimen for PV patients is fluconazole 300 mg 
per week combined with ketoconazole 2% twice a week for 2 weeks. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Pityriasis versicolor is a common, chronic, 
superficial fungal infection caused by Malassezia spp 
[1]. It is characterised by hyperpigmented, 
hypopigmented macules and patches on the face, 
upper trunk, back, chest paralleling the density of 
sebaceous gland. Several topical and systemic 
antifungal agents are effective against pityriasis 
versicolor. However, recurrence is common. Therefore, 
approaching an effective, safe and affordable treatment 
regimen should be taken in consideration.  
Our study aimed to assess and compare the 
efficacy and the safety of oral fluconazole combined 
with foam ketoconazole, oral itraconazole and foam 
ketoconazole alone.  
Material and Methods 
 
A group of 240 patients with pityriasis 
versicolor over 16 years old attending our out-patient 
dermatology clinic from January 2016 to December 
2016 were included in the study. Patients with other 
superficial and systemic fungal infections, history of 
treatment with oral antifungal drugs during the 
previous month or with topical anti-fungal drugs within 
1-week, pregnant females, and patients with the 
serious concurrent disease were excluded from the 
study 
Eligible patients were randomised to receive 
one of the following categories of treatment regimen: 
Category I: Fluconazole 300 mg a week for 2 weeks 
and foam ketoconazole 2% biweekly in 2 weeks; 
Category II: Itraconazole 200 mg daily for 1 week, 
 Tran Cam et al. Efficacy of Azole Antifungal in Treatment of Pityriasis Versicolor 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2019 Jan 30; 7(2):272-274.                                                                                                                                                         273 
 
Category III: foam ketoconazole 2% daily in 2 weeks.  
Clinical signs and symptoms such as pruritus, 
hypo or hyperpigmentation, and desquamation were 
classified (0 = none, 1 = mild, 2 = moderate, 3 = 
severe), lesion measurement (0: none, 1: < 10% BSA, 
2:10 - 30% BSA, 3: > 30% BSA).  
A group of 240 pityriasis versicolor patients 
were randomly classified into 3 groups: Fluconazole 
300 mg a week and 2% ketoconazole foam twice a 
week for 2 weeks (Group I), Itraconazole 200 mg daily 
for 1 week (Group II); Ketoconazole 2% foam daily for 
2 weeks (Group 3). 
 
 
Results 
 
During the study period, 240 patients were 
enrolled in our study: the itraconazole group, the 
fluconazole associated with ketoconazole shampoo 
group and the ketoconazole foam group. There were 
no statistically significant differences regarding age, 
sex, disease severity for patients in the two groups as 
shown in Table 1 (p > 0,05). 
Table 1: Characteristics of patients 
 Group 1 Group 2 Group 3 P 
Gender 
(Male/Female) 
50/30 54/26 52/28 > 0,05 
Age 
16-19 6/80 6/80 5/80 > 0,05 
20-29 39/50 40/80 43/80 
30-39 23/80 22/80 23/80 
40-49 8/80 9/80 6/80 
> 50 4/80 3/80 3/80 
Disease severity 
Mild 19/80 20/80 15/80 > 0,05 
Moderate 49/80 49/80 59/80 
Severe 12/80 11/80 6/80 
 
The mycological examination is considered 
the most important factor in determining the efficacy of 
treatment. The negative result showed that the patient 
had recovered from the microorganism despite still 
having skin lesions. It was reported in our study as 
shown in Table 2 that negative mycological 
examination was highest in group 1 (81.3%); lowest in 
group 3 (60%).  
Table 2: Clinical and mycological assessment after 4 weeks of 
therapy 
 
 
 
Group 1 (n = 80) Group 2 (n = 80) Group 3 (n = 80) 
Baseline 28 days Baseline 28 days baseline 28 days 
Scale Present 80 17 79 25 80 26 
Absent 0 63 1 55 0 54 
Pruritus Present 67 26 64 37 63 28 
Absent 13 54 16 43 17 52 
Disease activity score 4.7 ± 1.5 2.2 ± 1.2 4.5 ± 1.6 2.5 ± 1.4 4.6 ± 1.4 2.5 ± 1.2 
Decrease in DAS  2.5 ± 1.1 2.0 ± 1.0 2.1 ± 0.8 
Mycological 
culture 
Positive 80 15 80 27 80 32 
Negative  0 65 0 53 0 48 
 
It was also reported in Table 2 that 53/80 
patients (66.3%) treated with itraconazole 200 mg 
daily for 7 days have negative KOH examination. 
As reported in our research, the highest cure 
rate was observed in group 1 (81.2%), followed by 
Group 2 (66.3%) and Group 3 (60.0%).There were 
statistical significant difference meaning between 
Group 1 and Group 2 (p < 0,01), Group 1 and 3 (p < 
0,05). 
In our study, a new regimen-oral fluconazole 
300 mg a week combined with ketoconazole 2% foam 
3 times a week for 2 weeks was first applied. The 
overall cure rate after 4 weeks was 81.2%. It was 
lower than Badri T's study (90%), relapse rate was not 
assessed in both study. Compared with fluconazole 
treatment alone in Montero-Gei’s research, ninety 
patients with tineaversicolor were randomly assigned 
to treatment with either a single 450 mg dose of 
fluconazole, two 300mg doses of fluconazole given for 
one week, or itraconazole 200 mg daily for 7 days. At 
the end of treatment, the cure rate for itraconazole 
(20%) was significantly higher (P = 0.024) than that for 
fluconazole 450 mg (0%).  
 
Figure 1: Treatment efficacy after 4 weeks 
 
 
Discussion 
 
It was 91% in Talel Badri’s research on 
patients treated with oral fluconazole and 2% for 
ketoconazole [2]. 100% of patients had negative KOH 
result after 5weeks of ketoconazole cream 2% in 
Fonzo’s study [3]. It was demonstrated by Mehme 
Karakas’s study that 77% and 77.5% of patients 
treated with fluconazole 300 mg for 2 weeks have 
negative mycological result after 4 weeks, respectively 
[4], [5]. There were several studies in which 
fluconazole was applied in various durations and 
dosages in the treatment of tinea versicolor (450 
mg/single dose, 400 mg/single dose, 300 mg with a 1-
week interval, 300 mg a week for 2 weeks, 150mg a 
week for 4 weeks). In these studies, the mycological 
cure varied between 44%-100% [3]. Accordingly, the 
clinician may opt to use regimen 300 mg a week for 2 
weeks for treating tinea versicolor.  
There were several studies in which 
ketoconazole shampoo and foam was applied in 
treatment tinea versicolor. According to Di Fonzo [3], 
the cure rate was observed in 100% of patients after 2 
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weeks of ketoconazole shampoo 1% and 2%. It was 
81%, 55% and 72% in Rigoponlos (2007), Cantrell 
(2014) and Shi (2014)’s study [6], [7], [8].  
In our research, we have assessed one of the 
most common regimen antifungal drugs in Vietnam – 
itraconazole 200mg daily for 7 days. Kose et al. 
reported equivalent efficacy between a daily 200 mg 
dose of itraconazole for 7 days and a single 400 mg 
dose [9]. Kokturk et al., reported greater efficacy of 
400 mg of itraconazole a day over 3 days and 200 mg 
a day over 5 days than 400 mg in 1 day [5]. It was 
demonstrated in our study that the cure rate was seen 
in 66.3% of patients when they were treated by 
itraconazole 200mg daily for 7 days. When cure plus 
improvement was considered, response rates among 
the three treatment groups were comparable (97, 100, 
and 97% for fluconazole 450 mg, fluconazole 300 mg, 
and itraconazole, respectively) [10]. 
The unsimilar result between authors can be 
explained by the difference in criteria for efficacy 
assessment. The mycological cure rate was always 
higher than the clinical cure rate in all study groups. 
As a mycological cure is the only reliable criterion in 
assessing treatment efficacy, this implies that a 
proportion of patients rated as clinically improved 
were cured with residual colour changes (mostly 
hypopigmentation) [11], [12]. 
In conclusion, topical combined with systemic 
therapy is effective against tinea versicolor, especially 
extensive disease, frequent relapses, or history of 
failed topical treatment. In the current study, we found 
the highest mycological cure rate, 62.4%, with a single 
oral dose of fluconazole 300mg along with 
ketoconazole foam 2% twice a week, higher than with 
itraconazole 200 mg daily for one week (35.3%) and 
ketoconazole foam (37.5%). 
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